B cell receptor (BCR) signaling is a central pathway promoting the survival and proliferation
of normal and malignant B cells. Chronic lymphocytic leukemia (CLL) arises from mature B …

Introduction As a vital mechanism of survival, lymphopoiesis requires the collaboration of
different signaling molecules to orchestrate each step of cell development and maturation …

Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as ibrutinib
and idelalisib, are known to show activity in chronic lymphocytic leukemia (CLL) via their …

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma
(NHL). While traditional therapy is not considered curative, most patients experience an …

Abstract Phosphoinositide-3-kinase (PI3K) inhibitors have efficacy in lymphoid
malignancies; however, inflammatory and infectious toxicities can compromise the treatment …

This disclosure provides novel imidazopyridazine com pounds of formula (I) and
pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a …

Int. Cl. C07D 487/04(2006.01) A61P 19/02(2006.01) A61P 35/00(2006.01) C07D
519/00(2006.01) A61P 11/00(2006.01) A61P 29/00(2006.01) A61P 37/00(2006.01)(52) US …

Chronic lymphocytic leukemia (CLL) is the most common leukemia in developed countries. It
is characterized by the accumulation of CD5+ B lymphocytes in the peripheral blood, bone …

Summary Umbralisib tosylate (TGR-1202) is a next-generation oral phosphatidylinositol 3-
kinase δ (PI3Kδ) inhibitor under development at TG Therapeutics targeting the δ isoform …